The evolving role of antibody-drug conjugates in the treatment of urothelial carcinoma

Antibody Drug Conjugates for CancerПодробнее

Utilizing antibody-drug conjugates in the treatment of metastatic urothelial carcinomaПодробнее

Antibody-drug conjugates in urothelial carcinomaПодробнее

The future of antibody-drug conjugates in urothelial cancerПодробнее

Understanding Antibody Drug ConjugatesПодробнее

Metastatic urothelial cancer: clinical insights into trial data | Shilpa Gupta and Petros GrivasПодробнее

Part 11 - Evolution of Antibody Drug conjugates in cancer - Dr. Gail Phillips, USAПодробнее

The Evolution of Immuno Oncology I O Therapies Across the Urothelial Carcinoma Treatment LandscapeПодробнее

Improving Patient Outcomes in Urothelial Carcinoma With Novel Antibody–Drug ConjugatesПодробнее

Understanding the Evolving Treatment Landscape in Bladder CancerПодробнее

ADCs in the management of urothelial carcinomaПодробнее

Where do ADCs fit in the treatment landscape of urothelial carcinoma?Подробнее

Antibody Drug ConjugatesПодробнее

Therapeutic antibodies (Part 3): antibody-drug conjugatesПодробнее

HER2+ Breast Cancer: Evolution of Antibody-Drug ConjugatesПодробнее

Antibody Drug Conjugates in Metastatic Breast Cancer | Anthony Elias, MD | ESMO22 ColoradoПодробнее

Targeting EGFR-positive NSCLC with antibody-drug conjugatesПодробнее

Antibody-drug conjugates in gynecological cancersПодробнее

Evolving Paradigms of Hormone Receptor-Positive Breast Cancer: The Rise of Antibody-Drug ConjugatesПодробнее

What are antibody-drug conjugates and how do they work against cancer?Подробнее